KeyBanc Names Top Healthcare Stocks By Investing.com

KeyBanc Capital ranked Elanco, Hinge Health, Oddity Tech, Omnicell, and Progyny as its top five healthcare picks, spanning animal health, digital therapeutics, beauty tech, pharmacy automation, and fertility benefits. The news is mixed at the company level: Elanco beat on Q4 revenue and earnings, Oddity approved a $200 million buyback, while Omnicell missed EPS and Progyny issued FY2026 guidance below Street expectations. Analyst actions were also mixed, with several price target cuts and upgrades across the group.

Analysis

The ranking is less a clean “quality” statement than a dispersion map of healthcare business models under very different catalysts. The real signal is that capital is being rewarded where there is either visible self-help or monetization optionality: buybacks and beat/re-raise stories can work quickly, while subscale or mismanaged growth stories get punished even if the secular theme is intact. That makes the opportunity set more about relative positioning inside healthcare than a broad sector call.

ELAN looks like the most straightforward long because earnings momentum plus an improving capital allocation backdrop typically compresses the discount to larger animal-health peers over the next 1-2 quarters. ODD’s buyback is helpful, but if the ad-channel issue is real, the first derivative on growth is what matters; repurchases may slow the downside but won’t fully offset a demand shock if customer acquisition efficiency deteriorates. OMCL sits in the awkward middle: a modest revenue beat with an EPS miss usually triggers estimate resets, but if management can defend margins, the market may reward the installed-base durability after one more quarter.

PGNY is the weakest setup because guidance cuts in benefit-management models often force employers and brokers to re-evaluate plan economics, creating a slower burn of multiple compression that can last several quarters. The contrarian angle is that the market may be over-focusing on headline guidance misses and underappreciating which names have pricing power versus pure utilization exposure: HNGE can reaccelerate if employer adoption remains a budget-friendly substitute for in-person care, while OMCL benefits if hospitals keep pushing automation to offset labor pressure. The spread trade is therefore more compelling than outright longs in the weaker names.

Key Decisions for Investors

• Go long ELAN on any 1-2 day pullback; target 8-12% upside over 6-10 weeks if follow-through from the beat persists, with a tight 5% stop if the post-earnings bid fades.
• Pair trade: long ELAN / short PGNY for the next 1-3 months to isolate relative earnings revision momentum versus guidance credibility; expect asymmetric downside in PGNY if near-term commentary stays cautious.
• Buy OMCL only after the next management check-in or quarterly print confirms margin stabilization; downside risk is another estimate reset, but upside is a 10-15% rerating if the market accepts the revenue base as intact.
• Use ODD as a tactical short-term trade only if the buyback becomes active and sentiment stabilizes; otherwise avoid core positioning until there is evidence the ad-partner disruption is not a multi-quarter growth hit.
• For HNGE, consider a smaller starter long with a 3-6 month horizon; the setup works only if employer demand remains resilient, and the risk/reward improves if valuation has already discounted the mixed analyst backdrop.